13718-26-8
Chemical Structure
Sodium metavanadate, 99%
Synonym(s): Sodium vanadate(V), 99%
- CAS No.: 13718-26-8
- Formula:NaVO3
- Molecular Weight:121.93
InChIKey: RPMRIJNARKGEHE-UHFFFAOYSA-N
SMILES: O=[V](=O)([Na])=O
Biological Activity: Sodium metavanadate, 99% (Sodium vanadate (V), 99%) is an orally active phosphate structural analog and protein tyrosine phosphatase (PTPases) inhibitor. Sodium metavanadate, 99% mimics phosphate to interfere with phosphoprotein reactions, inhibits GAPDH, Na+/K+-ATPase and microbial membrane ATPase, and acts as a terminal electron acceptor for anaerobic respiration. Sodium metavanadate, 99% induces ROS production, G2/M phase arrest, mitochondrial membrane potential loss and apoptosis in breast cancer cells, and reduces tumor volume in tumor-bearing mice. Sodium metavanadate, 99% also exhibits oral insulin-sensitizing and metabolic regulatory activities, and reduces plasmodium parasitemia levels. Sodium metavanadate, 99% can be used in studies related to cadmium exposure-induced metabolic syndrome, plasmodium infection, breast cancer and type 1 diabetes[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sodium metavanadate, 99% | 99.34% | Sodium metavanadate, 99% (Sodium vanadate (V), 99%) is an orally active phosphate structural analog and protein tyrosine phosphatase (PTPases) inhibitor. Sodium metavanadate, 99% mimics phosphate to interfere with phosphoprotein reactions, inhibits GAPDH, Na+/K+-ATPase and microbial membrane ATPase, and acts as a terminal electron acceptor for anaerobic respiration. Sodium metavanadate, 99% induces ROS production, G2/M phase arrest, mitochondrial membrane potential loss and apoptosis in breast cancer cells, and reduces tumor volume in tumor-bearing mice. Sodium metavanadate, 99% also exhibits oral insulin-sensitizing and metabolic regulatory activities, and reduces plasmodium parasitemia levels. Sodium metavanadate, 99% can be used in studies related to cadmium exposure-induced metabolic syndrome, plasmodium infection, breast cancer and type 1 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bisconti L, et al. Reduction of vanadate to vanadyl by a strain of Saccharomyces cerevisiae. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 1997 Oct;10(4):239-46. [Content Brief]
- [2]. Sarmiento-Ortega VE, et al. Sodium metavanadate treatment improves glycogen levels in multiple tissues in a model of metabolic syndrome caused by chronic cadmium exposure in Wistar rats. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 2021 Apr;34(2):245-258.
- [3]. Brenda CT, et al. Ultrastructural alterations due to sodium metavanadate treatment in the blood stages of Plasmodium yoelii yoelii. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS). 2023 Dec;80:127314.
- [4]. Tian Y, et al. Anticancer effect of sodium metavanadate on murine breast cancer both in vitro and in vivo. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 2021 Jun;34(3):557-571.
- [5]. Cheta D, et al. The influence of sodium metavanadate on the process of diabetogenesis in BB rats. Journal of cellular and molecular medicine. 2003;7(4):447-54. [Content Brief]
